Issue 10

A BIO Preview Edition of The Pharma Navigator

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

What is the Cost of Developing Biologic Drugs?

Biologic drugs hold the potential to revolutionize biotech, offering new treatments for a range of diseases and conditions that were previously difficult or impossible to manage. For the remainder of this decade, the biologics industry could experience significant growth driven by the incidence of chronic diseases and the rise of autoimmune disorders due to aging populations and lifestyle changes – likely to fuel the demand for biologics as treatment options. 

Read more here.

FEATURED STORIES

Lilly Increases Investment at Indiana Site to $9 Billion to Boost API Production for Weight Loss & Diabetes 

Read more here.

WuXi Biologics Withdraws from 2024 BIO Convention Amid Geopolitical Tensions
Read more here.

New Joint Regulatory Plan to Streamline Biotechnology Oversight

Read more here.

Breakthrough in Pulmonary Fibrosis Treatment: GRI Bio's Promising Preclinical Results

Read more here.

Tourmaline Bio Trials Promising Cardiovascular Therapy

Read more here.

BIO Announces Major Restructuring and Staff Reduction

Read more here.

AstraZeneca Targets $80 Billion Revenue by 2030 

Read more here.

Sanofi Teams to Leverage OpenAI & Formation Bio to Boost Biopharma R&D

Read more here.

Merck Acquisition Provides Boost to Gene Therapy Capabilities

Read more here.

Biotech Stocks Surge Amid Public Health Concerns Over Avian Flu

Read more here.

AltruBio Secures Series B Funding for Autoimmune Regulator

Read more here.